Survey Supports Puma Biotechnology (PBYI) Nerlynx Bull Case - Citi; PT Lowered to $151
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
Go back to Survey Supports Puma Biotechnology (PBYI) Nerlynx Bull Case - Citi; PT Lowered to $151
September 17, 2018 4:33 PM EDT
Guggenheim analyst Michael Schmidt initiates coverage on Puma Biotechnology (NASDAQ: PBYI) with a Buy rating and a price target of $85.00.
For an analyst ratings summary and ratings history on Puma Biotechnology click here. For more ratings news on Puma Biotechnology click here.
Shares of Puma Biotechnology closed at $47.00 yesterday.
...
More
September 17, 2018 9:28 AM EDT
Today's Pre-Open Stock Movers
Senomyx, Inc. (NASDAQ: SNMX) 41% HIGHER; Firmenich and Senomyx, Inc. (NASDAQ: SNMX) today announced that they have entered into a definitive merger agreement under which Firmenich will acquire all of the outstanding common stock of Senomyx for $1.50 per share in cash. This represents a premium of approximately 43% over Senomyx's closing price on September 14, 2018 and a premium of approximately 39% based on the prior 30-trading day volume-weighted average price (VWAP). The proposed transaction has been unanimously approved by the Boards... More
September 17, 2018 5:17 AM EDT
Goldman Sachs analyst Paul Choi initiates coverage on Puma Biotechnology (NASDAQ: PBYI) with a Sell rating and a price target of $42.00.
The analyst initiates SMID Biotech sector at Neutral. He is negative on PBYI noting it is primarily trading on patient growth... More
